Monitoring CSF Proteome Alterations in Amyotrophic Lateral Sclerosis: Obstacles and Perspectives in Translating a Novel Marker Panel to the Clinic

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  von Neuhoff, Nils ^a   Oumeraci, Tonio ^a   Wolf, Thomas ^a,b   Kollewe, Katja ^a   Bewerunge, Peter ^b   Neumann, Boris ^c   Brors, Benedikt ^b   Bufler, Johannes ^a   Wurster, Ulrich ^a   Schlegelberger, Brigitte ^a   Dengler, Reinhard ^a   Zapatka, Marc ^b   Petri, Susanne ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c PROTEOME FACTORY AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CHROMOGRANIN; CHROMOGRANIN A; CYSTATIN C; NERVE GROWTH FACTOR INDUCIBLE PROTEIN; OSTEOPONTIN; PHOSPHOPROTEIN; PROTEIN; PROTEOME; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHROMATOGRAPHY; CLASSIFIER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PARAMAGNETIC BEAD CHROMATOGRAPHY; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PREDICTION; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN ISOLATION; RANDOM FOREST; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; UNIVARIATE ANALYSIS; UPREGULATION;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID PROTEINS; HUMANS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84866079814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044401     Document Type: Article

References (59)

1. Bruijn LI, Miller TM, Cleveland DW, (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723-749.
2. Pasinelli P, Brown RH, (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7: 710-723.
3. Brooks BR, Miller RG, Swash M, Munsat TL, (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 293-299.
4. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, et al. (2000) Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol. 57: 1171-1176.
5. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM, (2011) Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS ONE 6: e17947.
6. Blasco H, Corcia P, Moreau C, Veau S, Fournier C, et al. (2010) 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS ONE 5: e13223.
7. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA,et al. 2010 Establishing the proteome of normal human cerebrospinal fluid. PLoS ONE 5: e10980.
8. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, et al. (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95: 1461-1471.
9. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, et al. (2006) Identification of potential CSF biomarkers in ALS. Neurology 66: 1218-1222.
10. Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, et al. (2010) Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle & Nerve 42: 104-111.
11. Wilson KE, Ryan MM, Prime JE, Pashby DP, Orange PR, et al. (2004) Functional genomics and proteomics: application in neurosciences. J Neurol Neurosurg Psychiatry 75: 529-38.
12. Wilson ME, Boumaza I, Lacomis D, Bowser R, (2010) Cystatin C: A candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE 5: e15133.
13. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
14. Li X: PROcess: Ciphergen SELDI-TOF Processing. R package version 0.16-0. Bioconductor, Open Source Software for Bioinformatics. Available: http://www.bioconductor.org/packages/release/bioc/html/PROcess.html Accessed 2012 Aug 13.
15. Breiman L, (2001) Random Forests. Machine Learning 45: 5-32.
16. Liaw A, Wiener M, (2002) Classification and regression by Random Forest. R News 2/3: 18-22.
17. Sing T, Sander O, Beerenwinkel N, Lengauer T, (2005) ROCR: visualizing classifier performance in R. Bioinformatics. 21: 3940-3941.
18. Therneau TM, Atkinson B, (2009) rpart Recursive partitioning. R-package version 3 (1):: 45.
19. NextGen website. Available: http://www.nextgensciences.com/csf/csfdiscovery/Accessed 2012 Aug 13.
20. Sun L, Chen H, Hu C, Wang P, Li Y, et al. (2011) Identify biomarkers of neuropsychiatric systemic lupus erythematosus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with weak cation magnetic beads. J Rheumatol. 38: 454-61.
21. Liotta LA, Ferrari M, Petricoin E, (2003) Clinical proteomics: written in blood. Nature 425: 905.
22. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, et al. (2010) BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics 11: 91.
23. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, et al. (2008) T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model in ALS. Proc Natl Acad Sci U S A 105: 17913-17918.
24. Ranganathan S, Nicholl GC, Henry S, Lutka F, Sathanoori R, et al. (2007) Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler 8: 373-379.
25. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, et al. (2009) Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 27: 2199-2208.
26. Thompson EJ, (1995) Cerebrospinal fluid. J Neurol Neurosurg Psychiatry 59: 349-357.
27. Brettschneider J, Mogel H, Lehmensiek V, Ahlert T, Süssmuth S, et al. (2008) Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem Res 33: 2358-2363.
28. Pendyala G, Trauger SA, Kalisiak E, Ellis RJ, Siuzdak G, et al. (2009) Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys. J Proteome Res 8: 2253-2260.
29. Süssmuth SD, Brettschneider J, Ludolph AC, Tumani H, (2008) Biochemical markers in CSF of ALS patients.Curr Med Chem. 15: 1788-1801.
30. Tu GF, Aldred AR, Southwell BR, Schreiber G, (1992) Strong conservation of the expression of cystatin C gene in choroid plexus. Am J Physiol 263: R195-200.
31. George PM, Sheat JM, (1989) Cystatin C quantification in CSF. Clin Chem 35: 179-180.
32. Nagai A, Ryu JK, Terashima M, Tanigawa Y, Wakabayashi K, et al. (2005) Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res. 1066: 120-128.
33. Xu L, Sheng J, Tang Z, Wu X, Yu Y, et al. (2005) Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies. Neurobiol Dis 18: 152-165.
34. Okamoto K, Hirai S, Amari M, Watanabe M, Sakurai A, (1993) Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci Lett 162: 125-128.
35. Wada M, Uchihara T, Nakamura A, Oyanagi K, (1999) Bunina bodies in amyotrophic lateral sclerosis on Guam: a histochemical, immunohistochemical and ultrastructural investigation. Acta Neuropathol 98: 150-156.
36. Ono S, Shimizu N, Imai T, Mihori A, Nagao K, (2000) Increased cystatin C immunoreactivity in the skin in amyotrophic lateral sclerosis. Acta Neurol Scand 102: 47-52.
37. Okamoto K, Mizuno Y, Fujita Y, (2008) Bunina bodies in amyotrophic lateral sclerosis. Neuropathology 28: 109-115.
38. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, et al. (2006) Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 9: 108-118.
39. Taupenot L, Harper KL, O'Connor DT, (2003) The chromogranin-secretogranin family. N Engl J Med 348: 1134-1149.
40. Zhao Z, Lange DJ, Ho L, Bonini S, Shao B, et al. (2008) Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. Int J Med Sci 5: 92-99.
41. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, et al. (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64: 366-370.
42. Rüetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, et al. (2005) Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 196: 273-281.
43. Sugaya K, Greene R, Personett D, Robbins M, Kent C, et al. (1998) Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline. Neurobiol Aging 19: 351-361.
44. Ezzi SA, Urushitani M, Julien JP, (2007) Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem 102: 170-178.
45. Schrott-Fischer A, Bitsche M, Humpel C, Walcher C, Maier H, et al. (2009) Chromogranin peptides in amyotrophic lateral sclerosis. Regul Pept 152: 13-21.
46. Marksteiner J, Lechner T, Kaufmann WA, Gurka P, Humpel C, et al. (2000) Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease. Acta Neuropathol 100: 205-212.
47. Rangon CM, Haïk S, Faucheux BA, Metz-Boutigue MH, Fierville F, et al. (2003) Different chromogranin immunoreactivity between prion and a-beta amyloid plaque. Neuroreport 14: 755-758.
48. Lechner T, Adlassnig C, Humpel C, Kaufmann WA, Maier H, et al. (2004) Chromogranin peptides in Alzheimer's disease. Exp Gerontol 39: 101-113.
49. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, et al. (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24: 434-440.
50. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G, (1992) Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3: 201-203.
51. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, et al. (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69: 1569-1579.
52. Yang YR, Liu SL, Qin ZY, Liu FJ, Qin YJ, et al. (2008) Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome. Cell Mol Neurobiol 28: 737-744.
53. Jahn H, Wittke S, Zürbig P, Raedler TJ, Arlt S, et al. (2011) Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One 6: e26540.
54. Cho HJ, Kim S, Kwak SE, Kang TC, Kim HS, et al. (2009) Age-dependent pathogenesis of murine gammaherpesvirus 68 infection of the central nervous system. Mol Cells 27: 105-111.
55. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L, (2003) Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 53: 819-822.
56. Wootz H, Weber E, Korhonen L, Lindholm D, (2006) Altered distribution and levels of cathepsin D and cystatins in amyotrophic lateral sclerosis transgenic mice: possible roles in motor neuron survival. Neuroscience 143: 419-430.
57. Bos IW, Hoogland G, Meine Jansen CF, Willigen G, Spierenburg HA, et al. (2006) Increased glutamine synthetase but normal EAAT2 expression in platelets of ALS patients. Neurochem Int 48: 306-311.
58. Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y, et al. (2011) Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet 43: 132-137.
59. Bartolomucci A, Pasinetti GM, Salton SR, (2010) Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 170: 289-297.